Wanbury Faces Financial Struggles Amid Declining Sales and High Debt Concerns
Wanbury, a microcap in the Pharmaceuticals & Drugs sector, has recently adjusted its evaluation amid a challenging financial landscape. The company reported a notable decline in net sales for Q3 FY24-25, continuing a trend of negative performance over the past three quarters, raising concerns about its growth potential.
Wanbury, a microcap player in the Pharmaceuticals & Drugs industry, has recently undergone an evaluation adjustment reflecting its current financial landscape. The company has reported a very negative financial performance for the quarter ending Q3 FY24-25, marked by a significant decline in net sales of 17.21%. This downturn follows a trend of negative results over the last three consecutive quarters, raising concerns about its long-term growth potential.The company's financial metrics indicate a high debt burden, with a debt-to-equity ratio averaging 4.36 times, which may impact its operational flexibility. Despite a historical annual growth rate in net sales of 7.05% and operating profit at 11.65% over the past five years, the recent performance has not aligned with these trends. Additionally, the return on capital employed (ROCE) stands at 27.5, suggesting some level of attractive valuation, yet the stock is trading at a discount compared to its peers' average historical valuations.
The technical indicators also reflect a mildly bearish trend, with various factors contributing to this outlook. Notably, 76.74% of promoter shares are pledged, which could exert additional pressure on the stock in a declining market.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
